IRIS
CIARDIELLO, Fortunato
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 34.539
NA - Nord America 18.362
AS - Asia 14.500
SA - Sud America 2.382
AF - Africa 170
OC - Oceania 32
Continente sconosciuto - Info sul continente non disponibili 18
Totale 70.003
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 22.162
US - Stati Uniti d'America 18.063
SG - Singapore 5.081
IE - Irlanda 3.520
CN - Cina 3.035
HK - Hong Kong 2.490
BR - Brasile 2.027
IT - Italia 1.735
UA - Ucraina 1.725
VN - Vietnam 1.626
GB - Regno Unito 1.612
DE - Germania 1.284
FR - Francia 635
KR - Corea 606
FI - Finlandia 538
SE - Svezia 470
IN - India 430
GR - Grecia 352
TR - Turchia 346
JP - Giappone 247
CA - Canada 168
BD - Bangladesh 156
AR - Argentina 132
NL - Olanda 110
AT - Austria 92
ID - Indonesia 87
MX - Messico 79
PK - Pakistan 78
IQ - Iraq 71
PL - Polonia 70
EC - Ecuador 66
ES - Italia 50
BE - Belgio 47
CO - Colombia 40
ZA - Sudafrica 38
VE - Venezuela 34
MA - Marocco 33
CZ - Repubblica Ceca 30
SA - Arabia Saudita 29
PY - Paraguay 28
CH - Svizzera 26
CL - Cile 25
AU - Australia 23
JO - Giordania 19
EG - Egitto 17
IL - Israele 17
AE - Emirati Arabi Uniti 16
AZ - Azerbaigian 16
KE - Kenya 16
TH - Thailandia 16
UZ - Uzbekistan 16
EU - Europa 15
IR - Iran 15
PH - Filippine 15
TN - Tunisia 15
DZ - Algeria 14
NP - Nepal 13
AL - Albania 12
LT - Lituania 12
MY - Malesia 12
DO - Repubblica Dominicana 11
PE - Perù 11
BO - Bolivia 10
CR - Costa Rica 9
JM - Giamaica 9
TW - Taiwan 9
HU - Ungheria 8
KG - Kirghizistan 8
NZ - Nuova Zelanda 8
SN - Senegal 8
LB - Libano 7
HN - Honduras 6
HR - Croazia 6
KZ - Kazakistan 6
UY - Uruguay 6
AO - Angola 5
CG - Congo 5
PT - Portogallo 5
RO - Romania 5
TT - Trinidad e Tobago 5
BH - Bahrain 4
BY - Bielorussia 4
ET - Etiopia 4
LV - Lettonia 4
MK - Macedonia 4
OM - Oman 4
RS - Serbia 4
BB - Barbados 3
BG - Bulgaria 3
GT - Guatemala 3
GY - Guiana 3
KW - Kuwait 3
MM - Myanmar 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
CI - Costa d'Avorio 2
EE - Estonia 2
GA - Gabon 2
GI - Gibilterra 2
LK - Sri Lanka 2
Totale 69.960
Salva come PNG Salva come JPEG
Città #
Moscow 7.948
Dublin 3.502
Jacksonville 2.643
Hong Kong 2.457
San Jose 2.154
Singapore 2.011
Santa Clara 1.887
Chandler 1.692
Ashburn 797
Wilmington 694
Seoul 576
Chicago 566
Princeton 557
Ho Chi Minh City 547
Medford 493
Hefei 452
New York 394
Hanoi 373
Falls Church 334
Beijing 327
Boardman 311
San Mateo 292
Bengaluru 289
Naples 284
Dallas 283
Roxbury 257
Ann Arbor 250
Bremen 231
Munich 211
The Dalles 209
Los Angeles 207
Caserta 184
São Paulo 172
Woodbridge 161
Cambridge 124
Des Moines 120
Nanjing 97
Da Nang 92
Nuremberg 85
Houston 75
Haiphong 71
Jinan 64
Rio de Janeiro 64
Council Bluffs 59
Elora 59
Orem 58
Turku 57
Milan 55
Amsterdam 54
Mountain View 53
Belo Horizonte 51
Shanghai 51
Napoli 50
Vienna 50
Aversa 42
Dong Ket 42
Helsinki 42
Norwalk 42
Atlanta 41
Tokyo 41
Brussels 40
Düsseldorf 39
Tianjin 39
Rome 37
Guangzhou 36
Nanchang 36
Warsaw 36
Brasília 34
Curitiba 34
Frankfurt am Main 34
Lappeenranta 34
Brooklyn 33
Hải Dương 33
Chennai 31
Falkenstein 31
Montreal 31
London 30
San Francisco 29
Campinas 27
Changsha 27
Shenyang 27
Columbus 26
Kraków 26
Manchester 26
Quito 26
Jakarta 25
Memphis 25
Ninh Bình 25
Biên Hòa 24
Guarulhos 24
Istanbul 24
Thái Bình 24
Brno 23
Goiânia 23
Hillsboro 23
Auburn Hills 22
Porto Alegre 22
Ribeirão Preto 22
Salvador 22
Venice 22
Totale 36.536
Salva come PNG Salva come JPEG
Nome #
Epigenetic mechanisms underlying prostate cancer radioresistance 1.428
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 309
Comparative study of NGS platform ion torrent personal genome machine and therascreen rotor-gene Q for the detection of somatic variants in cancer. 248
Beyond N staging in colorectal cancer: Current approaches and future perspectives 223
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis 209
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. 206
ONCOLOGIA MEDICA 206
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells 205
A Multicenter, Open-Label Phase II Study of Metformin With Erlotinib in Second-Line Therapy of Stage IV Non-Small-Cell Lung Cancer Patients: Treatment Rationale and Protocol Dynamics of the METAL Trial. 205
AXL is an oncotarget in human colorectal cancer 195
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: what about stage IIC? 195
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells 192
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients 189
A trimodality, four-step treatment including chemotherapy, pleurectomy/decortication and radiotherapy in early-stage malignant pleural mesothelioma: A single-institution retrospective case series study 186
Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma—a pilot study. Curr Oncol 21, 3, june 2014 125-133 185
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures 185
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 184
Expression of c-MET in Estrogen Receptor Positive and HER2 Negative Resected Breast Cancer Correlated with a Poor Prognosis 183
Adjuvant chemoradiotherapy in patients with stage III-IV radically resected gastric cancer: a pilot study 183
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 183
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant 182
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer 181
A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells 180
CBX2 shapes chromatin accessibility promoting AML via p38 MAPK signaling pathway 177
A possible connective tissue primary lymphoepithelioma-like carcinoma (LELC). 177
Metabolomic approach for a rapid identification of natural products with cytotoxic activity against human colorectal cancer cells 177
Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: A propensity score-matched analysis 176
Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials 176
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer 174
Immunotherapy for head and neck cancer: Present and future 174
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 173
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors 173
Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study) 172
A preliminary study for quantitative assessment with HFUS (High-frequency ultrasound) of nodular skin melanoma breslow thickness in adults before surgery: Interdisciplinary team experience 172
Intraoperative ultrasound: "Alternative eye" in lymph nodal dissection in non-small cell lung cancer 171
Chronic inflammation and oxidative stress in human carcinogenesis 171
Clinical management of advanced gastric cancer: Role of new molecular drugs. 167
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. 167
A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics 166
Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. 165
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor 163
Modified blade: an interventional option in rigid bronchoscopy for non-resectable benign tracheal stenosis 162
Intraoperative ventilatory leak: Real-time guidance for management of air leak in lung cancer patients undergoing VATS lobectomy 162
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 162
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR 161
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 161
Prediction of preoperative intrathoracic adhesions for ipsilateral reoperations: sliding lung sign 160
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC 160
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 159
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 159
Cetuximab rechallenge plus avelumab in pretreated patients with RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial 159
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 159
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions 158
CARdioimaging in Lung Cancer PatiEnts Undergoing Radical RadioTherapy: CARE-RT Trial 158
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 158
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors 156
Histone lysine demethylase inhibition reprograms prostate cancer metabolism and mechanics 155
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients 155
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials 154
Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials 154
antitumor activity of zd6474, a VEGFR-2 and EGFR small molecule tyrosine kinase inhibitor in combination with SC-236, a cicloxigenase-2 inhibitor 153
Conversion chemotherapy followed by epatic resection in colorectal cancer with initially unresectable liver-limited metastases 152
Multiple Acquired Mutations Captured by Liquid Biopsy in the EGFR Addicted Metastatic Colorectal Cancer 152
Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer 151
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. 151
Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer 151
Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations 151
Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review 151
Clinical activity of regorafenib in elderly patients with recurrent glioblastoma 150
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients 150
AXL and MET Tyrosine Kinase Receptors Co-Expression as a Potential Therapeutic Target in Malignant Pleural Mesothelioma 150
Treatment of gastric cancer. 150
Biomarker-guided anti-egfr rechallenge therapy in metastatic colorectal cancer 150
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 150
Clinical management of metastatic colorectal cancer in the era of precision medicine 149
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 149
1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer. 148
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial 147
Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota 147
Intraoperative lung ultrasound improves subcentimetric pulmonary nodule localization during VATS: Results of a retrospective analysis 146
8-chloro-cAMP enhances the growth inhibitory effect of cytotoxic drugs in humancolon cancer cells 146
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 146
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 145
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial 145
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 145
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 145
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy 145
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 145
Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer 145
How immunotherapy has changed the continuum of care in hepatocellular carcinoma 145
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 144
Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis 144
TGF-β Modulated Pathways in Colorectal Cancer: New Potential Therapeutic Opportunities 143
Pimasertib hydrochloride 143
Microsatellite Instability: From the Implementation of the Detection to a Prognostic and Predictive Role in Cancers 143
8-chloro-cAMP inhibits smooth muscle cell proliferation in vitro and neointima formation induced by balloon injury in vivo 142
Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: A case report and a review of literature 142
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 141
Addition of metformin to anti-PD-1/PD-L1 drugs activates anti- tumor immune response in peripheral immune cells of NSCLC patients 141
Identification of Tissue miRNA Signatures for Pancreatic Ductal Adenocarcinoma 141
Totale 17.819
Salva come PNG Salva come JPEG
Categoria #
all - tutte 247.089
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 247.089
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021160 0 0 0 0 0 0 0 0 0 0 0 160
2021/20224.183 400 171 288 158 1.304 73 83 114 159 165 300 968
2022/20237.055 796 176 392 603 674 567 31 366 3.135 44 136 135
2023/20242.895 245 89 130 249 998 337 61 61 48 27 199 451
2024/20258.974 97 169 120 305 1.245 1.098 894 846 1.204 1.773 650 573
2025/202637.908 1.423 1.752 2.045 1.998 2.916 20.660 2.002 1.721 1.460 1.040 600 291
Totale 71.047